[Form 4] Jazz Pharmaceuticals, Inc. Insider Trading Activity
Patrick Kennedy, a director of Jazz Pharmaceuticals (JAZZ), received a grant of 3,507 restricted stock units under the issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to one ordinary share upon vesting; the units will vest in full on July 24, 2026 subject to the reporting person's continuous service and additional conditions.
Following the grant activity, the reporting person sold 1,959 shares at $111.2506 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, which reduced beneficial ownership from 8,661 shares to 6,702 shares.
Patrick Kennedy, direttore di Jazz Pharmaceuticals (JAZZ), ha ricevuto una concessione di 3,507 unit脿 azionarie vincolate ai sensi del "2007 Amended and Restated Non-Employee Directors Stock Award Plan" dell'emittente. Ogni unit脿 azionaria vincolata rappresenta il diritto condizionato a una azione ordinaria al momento del vesting; le unit脿 matureranno integralmente il 24 luglio 2026, soggette alla continuit脿 di servizio della persona che effettua la comunicazione e ad ulteriori condizioni.
Dopo la concessione, la persona segnalante ha venduto 1,959 azioni a $111.2506 per azione per far fronte agli obblighi fiscali derivanti dal vesting di unit脿 azionarie vincolate precedentemente assegnate, riducendo la partecipazione effettiva da 8,661 azioni a 6,702 azioni.
Patrick Kennedy, director de Jazz Pharmaceuticals (JAZZ), recibi贸 una concesi贸n de 3,507 unidades de acciones restringidas en virtud del "2007 Amended and Restated Non-Employee Directors Stock Award Plan" del emisor. Cada unidad restringida representa el derecho contingente a una acci贸n ordinaria al consolidarse; las unidades se consolidar谩n en su totalidad el 24 de julio de 2026, sujeto al servicio continuo de la persona informante y a condiciones adicionales.
Tras la concesi贸n, la persona informante vendi贸 1,959 acciones a $111.2506 por acci贸n para cubrir obligaciones fiscales derivadas del vesting de unidades de acciones restringidas concedidas anteriormente, reduciendo la propiedad beneficiaria de 8,661 acciones a 6,702 acciones.
Jazz Pharmaceuticals(JAZZ)鞚� 鞚挫偓鞚� Patrick Kennedy電� 氚滍枆鞚胳潣 "2007 Amended and Restated Non-Employee Directors Stock Award Plan"鞐� 霐半澕 3,507臧滌潣 鞝滍暅攵� 欤检嫕雼渼毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� 鞝滍暅攵� 欤检嫕雼渼電� 氩犾姢韺� 鞁� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 頃措嫻 雼渼電� 氤搓碃鞚胳潣 瓿勳啀 攴茧 氚� 旮绊儉 臁瓣贝鞚� 於╈”霅橂姅 瓴冹潉 鞝勳牅搿� 2026雲� 7鞗� 24鞚�鞐� 鞝勲秬 氩犾姢韸鸽惄雼堧嫟.
攵�鞐� 鞚错泟 氤搓碃鞚胳潃 鞚挫爠鞐� 攵�鞐悳 鞝滍暅攵� 欤检嫕雼渼鞚� 氩犾姢韺呾溂搿� 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 欤茧嫻 $111.2506鞐� 1,959欤�毳� 毵る弰頃橃棳 鞁れ 氤挫湢 欤检嫕鞚� 8,661欤�鞐愳劀 6,702欤�搿� 欷勳榾鞀惦媹雼�.
Patrick Kennedy, administrateur de Jazz Pharmaceuticals (JAZZ), a re莽u une attribution de 3,507 unit茅s d'actions restreintes dans le cadre du "2007 Amended and Restated Non-Employee Directors Stock Award Plan" de l'茅metteur. Chaque unit茅 d'actions restreintes repr茅sente un droit conditionnel 脿 une action ordinaire lors de l'acquisition; les unit茅s seront int茅gralement acquises le 24 juillet 2026, sous r茅serve de la continuit茅 de service de la personne d茅clarante et d'autres conditions.
Apr猫s l'attribution, la personne d茅clarante a vendu 1,959 actions au prix de $111.2506 par action pour s'acquitter des obligations fiscales r茅sultant de l'acquisition d'unit茅s d'actions restreintes pr茅c茅demment attribu茅es, r茅duisant la d茅tention b茅n茅ficiaire de 8,661 actions 脿 6,702 actions.
Patrick Kennedy, Direktor von Jazz Pharmaceuticals (JAZZ), erhielt eine Zuteilung von 3,507 Restricted Stock Units im Rahmen des vom Emittenten festgelegten "2007 Amended and Restated Non-Employee Directors Stock Award Plan". Jede Restricted Stock Unit begr眉ndet das bedingte Recht auf eine Stammaktie bei Vesting; die Einheiten werden vorbehaltlich der fortlaufenden Dienstzeit der meldenden Person und weiterer Bedingungen am 24. Juli 2026 vollst盲ndig vesten.
Im Anschluss an die Zuteilung verkaufte die meldende Person 1,959 Aktien zu je $111.2506, um steuerliche Verpflichtungen aus dem Vesting zuvor zugeteilter Restricted Stock Units zu erf眉llen, wodurch das wirtschaftliche Eigentum von 8,661 Aktien auf 6,702 Aktien sank.
- Grant of 3,507 restricted stock units under the Issuer's 2007 Non-Employee Directors Stock Award Plan
- RSUs vest in full on July 24, 2026, providing a future economic interest contingent on service and conditions
- Sale of 1,959 shares at $111.2506 to satisfy tax obligations tied to prior RSU vesting
- Reported beneficial ownership decreased from 8,661 shares to 6,702 shares following the sale
Insights
TL;DR: Routine director equity grant and tax-related sale; modest change in reported beneficial holdings, no debt or performance metrics disclosed.
The Form 4 shows a grant of 3,507 restricted stock units that convert to ordinary shares upon vesting and a subsequent sale of 1,959 shares at $111.2506 to cover tax obligations. This filing documents equity compensation mechanics for a non-employee director and a tax-withholding sale tied to vesting. The change in reported beneficial ownership from 8,661 to 6,702 shares is explicit in the filing; there are no additional financial results or corporate actions disclosed here.
TL;DR: Standard director award under the company plan and a compensatory tax-related disposition; disclosure aligns with Section 16 requirements.
The submission documents a board director receiving equity under the company's 2007 non-employee directors plan with vesting conditions dated July 24, 2026. The sale of 1,959 shares is explicitly described as being executed to satisfy tax obligations arising from vesting. Both the grant and the tax-sale are typical governance/compensation events and are reported on separate lines as required; no unusual governance actions or exceptions are indicated in the form.
Patrick Kennedy, direttore di Jazz Pharmaceuticals (JAZZ), ha ricevuto una concessione di 3,507 unit脿 azionarie vincolate ai sensi del "2007 Amended and Restated Non-Employee Directors Stock Award Plan" dell'emittente. Ogni unit脿 azionaria vincolata rappresenta il diritto condizionato a una azione ordinaria al momento del vesting; le unit脿 matureranno integralmente il 24 luglio 2026, soggette alla continuit脿 di servizio della persona che effettua la comunicazione e ad ulteriori condizioni.
Dopo la concessione, la persona segnalante ha venduto 1,959 azioni a $111.2506 per azione per far fronte agli obblighi fiscali derivanti dal vesting di unit脿 azionarie vincolate precedentemente assegnate, riducendo la partecipazione effettiva da 8,661 azioni a 6,702 azioni.
Patrick Kennedy, director de Jazz Pharmaceuticals (JAZZ), recibi贸 una concesi贸n de 3,507 unidades de acciones restringidas en virtud del "2007 Amended and Restated Non-Employee Directors Stock Award Plan" del emisor. Cada unidad restringida representa el derecho contingente a una acci贸n ordinaria al consolidarse; las unidades se consolidar谩n en su totalidad el 24 de julio de 2026, sujeto al servicio continuo de la persona informante y a condiciones adicionales.
Tras la concesi贸n, la persona informante vendi贸 1,959 acciones a $111.2506 por acci贸n para cubrir obligaciones fiscales derivadas del vesting de unidades de acciones restringidas concedidas anteriormente, reduciendo la propiedad beneficiaria de 8,661 acciones a 6,702 acciones.
Jazz Pharmaceuticals(JAZZ)鞚� 鞚挫偓鞚� Patrick Kennedy電� 氚滍枆鞚胳潣 "2007 Amended and Restated Non-Employee Directors Stock Award Plan"鞐� 霐半澕 3,507臧滌潣 鞝滍暅攵� 欤检嫕雼渼毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� 鞝滍暅攵� 欤检嫕雼渼電� 氩犾姢韺� 鞁� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 頃措嫻 雼渼電� 氤搓碃鞚胳潣 瓿勳啀 攴茧 氚� 旮绊儉 臁瓣贝鞚� 於╈”霅橂姅 瓴冹潉 鞝勳牅搿� 2026雲� 7鞗� 24鞚�鞐� 鞝勲秬 氩犾姢韸鸽惄雼堧嫟.
攵�鞐� 鞚错泟 氤搓碃鞚胳潃 鞚挫爠鞐� 攵�鞐悳 鞝滍暅攵� 欤检嫕雼渼鞚� 氩犾姢韺呾溂搿� 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 欤茧嫻 $111.2506鞐� 1,959欤�毳� 毵る弰頃橃棳 鞁れ 氤挫湢 欤检嫕鞚� 8,661欤�鞐愳劀 6,702欤�搿� 欷勳榾鞀惦媹雼�.
Patrick Kennedy, administrateur de Jazz Pharmaceuticals (JAZZ), a re莽u une attribution de 3,507 unit茅s d'actions restreintes dans le cadre du "2007 Amended and Restated Non-Employee Directors Stock Award Plan" de l'茅metteur. Chaque unit茅 d'actions restreintes repr茅sente un droit conditionnel 脿 une action ordinaire lors de l'acquisition; les unit茅s seront int茅gralement acquises le 24 juillet 2026, sous r茅serve de la continuit茅 de service de la personne d茅clarante et d'autres conditions.
Apr猫s l'attribution, la personne d茅clarante a vendu 1,959 actions au prix de $111.2506 par action pour s'acquitter des obligations fiscales r茅sultant de l'acquisition d'unit茅s d'actions restreintes pr茅c茅demment attribu茅es, r茅duisant la d茅tention b茅n茅ficiaire de 8,661 actions 脿 6,702 actions.
Patrick Kennedy, Direktor von Jazz Pharmaceuticals (JAZZ), erhielt eine Zuteilung von 3,507 Restricted Stock Units im Rahmen des vom Emittenten festgelegten "2007 Amended and Restated Non-Employee Directors Stock Award Plan". Jede Restricted Stock Unit begr眉ndet das bedingte Recht auf eine Stammaktie bei Vesting; die Einheiten werden vorbehaltlich der fortlaufenden Dienstzeit der meldenden Person und weiterer Bedingungen am 24. Juli 2026 vollst盲ndig vesten.
Im Anschluss an die Zuteilung verkaufte die meldende Person 1,959 Aktien zu je $111.2506, um steuerliche Verpflichtungen aus dem Vesting zuvor zugeteilter Restricted Stock Units zu erf眉llen, wodurch das wirtschaftliche Eigentum von 8,661 Aktien auf 6,702 Aktien sank.
FAQ
What did Patrick Kennedy report on the JAZZ Form 4?
When do the granted RSUs vest for Patrick Kennedy?
How many JAZZ shares does Kennedy own after the reported transactions?
At what price were the shares sold to cover taxes?
Under what plan were the restricted stock units granted?
